Skip to main content

Table 2 Uni- and multivariate Cox regression analysis

From: Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the ‘TOaSTT’ database

Variables

OS

PFS

TTS

Univariate

Multivariate

Univariate

Multivariate

Univariate

Multivariate

p value

p value

HR (95% CI)

p value

p value

HR (95% CI)

p value

p value

HR (95% CI)

Cinical metastatic status (OPD, palliative intent)

0.006

0.002

2.03 (1.30–3.17)

0.002

0.334

 

0.053

0.938

1.0 (0.56–1.81)

Initial stage (I–IV)

0.567

0.402

  

0.561

  

Metastatic development (synchronous vs. metachronous)

0.802

0.895

  

0.653

  

Previous lines of systemic treatment (1 vs. > 1)

0.166

0.109

0.048

0.033

1.7 (1.05–2.77)

0.093

0.152

1.57 (0.84–2.92)

Metastatic burden (1, 2–5, 6–10, > 10)

0.461

0.062

0.759

 

0.051

0.686

1.10 (0.741.64)

Affected organs (1 vs. > 1)

0.03

0.633

0.004

0.023

2.04 (1.10–3.79)

0.026

0.031

2.53 (1.09–5.89)

Location of metastases (cranial vs. extracranial)

0.201

0.827

0.155

0.757

 

0.48

  

Histology subtype (SqCC, ADC, LCNEC, adenosquamous, unknown)

0.952

0.554

  

0.447

  

Gene mutation (yes vs. no)

0.834

0.992

  

0.696

  

Status of primary tumor (controlled vs. progressive)

0.973

0.701

  

0.824

  

Targeted therapy (IT, TT, AAT)

0.855

0.424

  

0.64

  

SRT location (cranial, extracranial, both)

0.25

0.149

0.571

 

0.767

  

Number of SRT treated metastases (1–5)

0.642

0.993

  

0.509

  

Start targeted therapy (before, during, after SRT)

0.239

0.436

  

0.299

  

Targeted therapy paused during SRT (yes vs no)

0.645

0.734

  

0.104

0.393

1.32 (0.75–2.34)

  1. p < 0.05 is significant
  2. HR  hazard ratio, CI confidence interval, TT targeted therapy, IT immunotherapy, AAT antiangiogenic therapy, PARPi  PARP-inhibitor